Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04888442
Other study ID # PB02
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 26, 2020
Est. completion date March 28, 2022

Study information

Verified date May 2021
Source Chongqing Precision Biotech Co., Ltd
Contact Xiaoxi zhou, M.D
Phone 86-27-83665027
Email cello316@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in adults with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.


Description:

This is a single-center, single-arm, open-label study. The study plans to set up 3 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 adults with relapsed or refractory B-ALL.pCAR-19B will be infused to the subject by intravenous infusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date March 28, 2022
Est. primary completion date January 30, 2022
Accepts healthy volunteers No
Gender All
Age group 22 Years to 70 Years
Eligibility Inclusion Criteria: 1. Diagnosed with B-ALL,and meet one of the following conditions: 1. First-line or multiple-line salvage chemotherapy did not achieve complete remission; 2. Early relapse after complete remission (<12 months), or late relapse after complete remission (=12 months) and complete remission has not been achieved after 1 course of treatment; 3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation; 2. Ph+ALL patients should also receive at least two TKI treatments; 3. For allogeneic hematopoietic stem cell transplant subjects, the following conditions must be met: 1. Allo-HSCT takes =6 months before pCAR-19B infusion; 2. No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection; 4. Express CD19; 5. 22~70 years old, no gender limit; 6. The expected survival time is more than 12 weeks; 7. KPS>60; 8. No serious mental disorders; 9. The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is =50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine=2.0×ULN; 3. Liver function: ALT and AST =3.0×ULN; 4. Total bilirubin and alkaline phosphatase=2.0×ULN (Gilbert syndrome = 3.0×ULN); 5. Blood oxygen saturation>92%. 10. Have standards for apheresis or venous blood collection, and no other cell collection contraindications; 11. The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: 1. With central nervous system disease at the time of screening; 2. Have received CAR-T therapy or other genetically modified cell therapy; 3. Participated in other clinical studies within 1 month before screening; 4. Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 5. Have received a live attenuated vaccine within 4 weeks before screening; 6. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; 7. Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred =6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. 8. Uncontrollable infection in the 2 weeks before screening; 9. Active autoimmune diseases; 10. Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer; 11. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; 12. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion; 13. Other situations considered by the researcher to be unsuitable to participate in the study.

Study Design


Related Conditions & MeSH terms

  • Acute Lymphoblastic Leukemia, in Relapse
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Refractory Acute Lymphoblastic Leukemia

Intervention

Biological:
pCAR-19B cells
Drug: pCAR-19B cells; Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Locations

Country Name City State
China Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Chongqing Precision Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability] Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) 28 days
Primary Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability] Dose-limiting toxicity after cell infusion 28 days
Secondary Objective response rate after pCAR-19B infusion [Effectiveness] Objective response rate includes CR, CRi 3 months
Secondary AUCS of pCAR-19B cells [Cell dynamics] AUCS is defined as the area under the curve in 28 days and 90 days 3 months
Secondary CMAX of pCAR-19B cells [Cell dynamics] CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood 3 months
Secondary TMAX of pCAR-19B cells [Cell dynamics] TMAX is defined as the time to reach the highest concentration 3 months
Secondary Pharmacodynamics of pCAR-19B cells[Cell dynamics] Cytokines such as hs-CRP, IL-6 levels 3 months
Secondary Immunogenicity of pCAR-19B cells Anti-CAR antibody 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03620058 - CART22 Alone or in Combination With huCART19 for ALL Phase 1
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Recruiting NCT03241940 - Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT02146924 - Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT04000698 - Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias Phase 3
Completed NCT03096782 - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Phase 2
Completed NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Phase 2
Completed NCT04888468 - Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Phase 1
Terminated NCT03094611 - Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT02392572 - ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03263572 - Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Phase 2
Terminated NCT03519984 - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Phase 1
Completed NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia Phase 2
Active, not recruiting NCT01619761 - NK Cells in Cord Blood Transplantation Phase 1
Completed NCT01865617 - Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT02727803 - Personalized NK Cell Therapy in CBT Phase 2
Terminated NCT01620216 - Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Phase 2
Recruiting NCT04325841 - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Phase 2